Intraperitoneal radioimmunotherapy: Auger electron emitters for solid tumors

Immunotherapy

Volumn 3, Issue 4, 2011, Pages 491-494

  Baranowska Kortylewicz, Janina ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

Author keywords

anti CEA 35A7; Auger electron; iodine 125; peritoneal carcinomatosis; radioimmunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; IODINE 125; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 35A7 I 125; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CYTOREDUCTIVE SURGERY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; DRUG UPTAKE; ELECTRON RADIATION; HUMAN; NONHUMAN; NOTE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIOIMMUNOTHERAPY; WHOLE BODY SCINTISCANNING;

EID: 79953830567     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.11.11     Document Type: Note

References (20)

1. 131 labeled monoclonal antibodies. Int. J. Radiat. Oncol. Biol. Phys. 16, 405-413 (1989).
2. 90Y-labeled monoclonal antibody B72.3 after intraperitoneal administration. J. Natl Cancer Inst. 83, 1629-1636 (1991).
3. Buckman R, De Angelis C, Shaw P et al.: Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3. Gynecol. Oncol. 47, 102-109 (1992).
4. 131 MOv18, clinical results in patients with minimal residual disease of ovarian cancer. Eur. J. Cancer 31A, 686-690 (1995).
5. Mariani G, Molea N, Bacciardi D et al.: Initial tumor targeting, biodistribution, and pharmacokinetic evaluation of the monoclonal antibody PAM4 in patients with pancreatic cancer. Cancer Res. 55, S5911-S5915 (1995).
6. Meredith RF, Partridge EE, Alvarez RD et al.: Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium177CC49. J. Nucl. Med. 37, 1491-1496 (1996).
7. Laitinen JO, Kairemo KJ, Jekunen AP, Korppi-Tommola T, Tenhunen M: The effect of three dimensional activity distribution on the dose planning of radioimmunotherapy for patients with advanced intraperitoneal pseudomyxoma. Cancer 80, 2545-2552 (1997).
8. 131-labeled anti-CEA monoclonal antibody. J. Nucl. Med. 38, 257-260 (1997).
9. Buijs WC, Tibben JG, Boerman OC et al.: Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration. Eur. J. Nucl. Med. 25, 1552-1561 (1998).
10. 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer, effect of dose and EDTA coadministration on pharmacokinetics and toxicity. Clin. Cancer Res. 5, 953-961 (1999).
11. 131I-labelled monoclonal antibody therapy in patients with intraperitoneal pseudomyxoma. Nucl. Med. Commun. 21, 355-360 (2000).
12. Alexander C, Holländer M, Schmidt W, Kirsch CM: Kinetics and dosimetry of monoclonal antibody MAb-170, evaluation of possibilities for intraperitoneal radioimmunotherapy. Nuklearmedizin 40, 207-214 (2001).
13. van Zanten-Przybysz I, Molthoff CF, Roos JC et al.: Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18, i.v. vs. i.p. Int. J. Cancer 92, 106-114 (2001).
14. 90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J. Clin. Oncol. 24, 571-578 (2006).
15. Andersson H, Cederkrantz E, Bäck T et al.: Intraperitoneal α-particle radioimmunotherapy of ovarian cancer patients, pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2 - a Phase I study. J. Nucl. Med. 50, 1153-1160 (2009).
16. Michel RB, Castillo ME, Andrews PM, Mattes MJ: In vitro toxicity of A-431 carcinoma cells with antibodies to epidermal growth factor receptor and epithelial glycoprotein-1 conjugated to radionuclides emitting low-energy electrons. Clin. Cancer Res. 10, 5957-5966 (2004).
17. Pouget JP, Santoro L, Raymond L et al.: Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by auger electrons. Radiat. Res. 192-200 (2008).
18. Herlyn M, Steplewski Z, Herlyn D, Koprowski H: Colorectal carcinoma-specific antigen, detection by means of monoclonal antibodies. Proc. Natl Acad. Sci. USA 76, 1438-1442 (1979).
19. 125I-labeled monoclonal antibodies. J. Nucl. Med. 51, 1748-1755 (2010).
20. Ferris RL, Jaffee EM, Ferrone S: Tumor antigen-targeted, monoclonal antibody-based immunotherapy, clinical response, cellular immunity, and immunoescape. J. Clin. Oncol. 28, 4390-4399 (2010).